CHEMED CORP (CHE): Results of Operations and Financial Condition
CHEMED CORP (CHE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 che-20260728xex99.htm EX-99 Exhibit 99 CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Second-Quarter 2026 Results Full-Year Guidance Increased Due Mainly to VITAS Outperformance CINCINNATI, July 28, 2026— Chemed Corporation (Chemed) (NYSE: CHE ), whic
How this was made
The 30-second read
Why it matters
VITAS delivered stronger growth metrics (net patient revenue, ADC, admissions) and improved adjusted EBITDA margin excluding Medicare Cap, while the company increased full-year guidance mainly due to VITAS outperformance and share repurchases.
Market read
Traders can update CHE’s FY earnings expectations using the guidance increase and the disclosed drivers (VITAS outperformance, Medicare Cap dynamics, and buybacks).
What to watch
Medicare Cap billing limitation swung sharply year over year (accrual down vs prior year), so some of the guidance lift could be sensitive to future Medicare Cap utilization and provider-level cushions.
Background
Chemed operates VITAS (end-of-life care) and Roto-Rooter (plumbing and drain cleaning). The 8-K reports Q2 2026 results and updates full-year guidance.
Ticker impact
Chemed reported Q2 2026 results and increased full-year guidance, citing materially improved VITAS performance and share repurchases.
Likely positive bias for CHE as traders reprice FY EPS expectations around the guidance increase.
The filing discloses multiple Q2 beats (revenue, GAAP and adjusted EPS) and explicitly states guidance was increased due mainly to VITAS outperformance, with additional detail on Medicare Cap dynamics and repurchases.
Market effects
Provides read-through on demand and reimbursement dynamics in end-of-life care providers, especially Medicare Cap cushion and ADC/admissions trends.
No specific regional catalyst beyond company-level operating metrics.
Limited global relevance; primarily US healthcare reimbursement and senior care operations.
Counterpoint
Roto-Rooter was essentially flat on adjusted EBITDA and margins declined, so consolidated upside may be more dependent on VITAS than investors expect.
Key entities
- issuerChemed Corporation
Reported Q2 2026 operating results, disclosed Medicare Cap billing limitation details, and increased full-year guidance.
- operating_segmentVITAS Healthcare Corporation
End-of-life care segment with higher net patient revenue, admissions, and adjusted EBITDA margin excluding Medicare Cap.
- operating_segmentRoto-Rooter
Commercial and residential plumbing segment with revenue growth but essentially flat adjusted EBITDA and margin decline.
